Richard Kershen, MD
Urogynecology and Reconstructive Pelvic Surgery · Hartford, CTNPI 1972527158
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,023 of the $28,177 with a category attached, or 88.8%. 11 manufacturers reported payments, led by Boston Scientific at 57.3% of the total. Reporting peaked in 2022 at $10,522 and has fallen 96.3% since, to $385 in 2025.
Across 112 payments — averaging $251.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$16K
- AbbVie$11K
- Axonics, Inc.$648
- Medtronic$318
- Coloplast$246
- Dentsply IH AB$123
- plus $136 from 5 others
What the payments were for
- Speaking & faculty fees$25,02389%
- Travel & lodging$1,3945%
- Food & beverage$1,6836%
- Education$400%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 52 | $16,146 |
| AbbVie(2 entities) | 30 | $10,560 |
| Axonics, Inc. | 12 | $648 |
| Medtronic | 6 | $318 |
| Coloplast | 4 | $246 |
| Dentsply IH AB | 3 | $123 |
| Teleflex LLC | 1 | $38 |
| Caldera Medical, Inc | 1 | $37 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Rochester Medical Corporation | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$10,235
- AMS 700 CXR RTE KIT$6,116
- TACTRA$2,900
- GENERAL ERECTILE DYSFUNCTION$2,400
- ADVANCE$2,100
- AMS$1,925
- Axonics r-SNM System$473
- ALTAVIVA$190
- TITAN$173
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 87 | $75,270 |
| MyrbetriqMirabegron | 81 | $51,798 |
| Mirabegron ErMirabegron | 26 | $10,645 |
| Trospium Chloride ErTrospium Chloride | 25 | $3,515 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 52 | $2,737 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $2,647 |
| Oxybutynin Chloride ErOxybutynin Chloride | 116 | $2,464 |
| Trospium Chloride | 35 | $2,299 |
| Methenamine Hippurate | 16 | $1,875 |
| Tamsulosin Hcl | 143 | $1,740 |
| Solifenacin Succinate | 40 | $1,478 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 117 | $914 |
| NitrofurantoinNitrofurantoin Macrocrystal | 41 | $902 |
| Estradiol | 17 | $875 |
| Cephalexin | 158 | $874 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Hartford
- Elena Tunitsky BittonHartford$9K
- Elisabeth SappenfieldHartford$2K
- Nicole WoodHartford$1K
- Noelle WaldschmidtHartford$1K
- Dmitry VolkinWaterford$15K
- Oz HarmanliNew Haven$9K
- Andrea RussoDanbury$8K
- Elisha JacksonNew Haven$4K
- Mark PrestonWaterbury$2K
- Jaclyn MunozNorwalk$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.